Sunday 11 October 2026
Export all LLY data to Excel Powerpack
Eli Lilly and Company
LLY Healthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 26.2%, free cash flow grew 458.1% and total debt rose 37.6%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for five.
1,179.27
9.67
+0.83%
Follow LLY
Eli Lilly and Company (LLY) SEC filings, changes and red flags
Red flags
-
Officer departure
Eli Lilly and Company reported the departure of an officer or director
Filings
| Form | Period | Filed | What it reports | Flags |
|---|---|---|---|---|
| 10-Q | Jun 30, 2026 |
P1I2: 10 added · 3 removed · 21 modified P2I1A: no material changes, the filing says |
||
| 8-K | Aug 5, 2026 | 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits | ||
| 8-K | May 20, 2026 | 8.01 Other events; 9.01 Financial statements and exhibits | ||
| 8-K | May 4, 2026 | 5.07 Submission of matters to a vote of security holders | ||
| 10-Q | Mar 31, 2026 | |||
| 8-K | Apr 30, 2026 | 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits | ||
| 10-K | Dec 31, 2025 |
1: 9 added · 10 removed · 61 modified 1A: 11 added · 2 removed · 60 modified 7: 16 added · 39 removed · 39 modified |
||
| 8-K | Feb 4, 2026 | 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits | ||
| 8-K | Nov 18, 2025 | 5.02 Departure or appointment of directors or officers | Officer departure | |
| 10-Q | Sep 30, 2025 | |||
| 8-K | Oct 30, 2025 | 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits | ||
| 10-Q | Jun 30, 2025 | |||
| 10-K | Dec 31, 2024 |